| - GRCh37:
- ChrMT:5794-14876
- GRCh38:
- ChrMT:5794-14876
| MT-CYB, MT-ND3, MT-TL2, MT-TR, MT-TS1, MT-TS2, MT-TY, MT-ATP6, MT-ATP8, MT-ND4, MT-ND4L, MT-ND5, MT-TG, MT-TH, MT-ND6, MT-TC, MT-TD, MT-CO1, MT-CO2, MT-CO3, MT-TE, MT-TK | | Primary dilated cardiomyopathy, Macrocytic dyserythropoietic anemia | Likely pathogenic (Nov 4, 2014) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:6468-15586
- GRCh38:
- ChrMT:6468-15586
| MT-ATP6, MT-ATP8, MT-CO1, MT-CO2, MT-CO3, MT-CYB, MT-ND3, MT-ND4, MT-ND4L, MT-ND5, MT-ND6, MT-TD, MT-TE, MT-TG, MT-TH, MT-TK, MT-TL2, MT-TR, MT-TS1, MT-TS2 | | Mitochondrial disease | Pathogenic (May 22, 2017) | no assertion criteria provided |
| - GRCh37:
- ChrMT:8839-14895
- GRCh38:
- ChrMT:8839-14895
| MT-ATP6, MT-CO3, MT-CYB, MT-ND5, MT-ND6, MT-TE, MT-TG, MT-TS2, MT-ND3, MT-ND4, MT-ND4L, MT-TH, MT-TL2, MT-TR | | Mitochondrial disease | Pathogenic (May 22, 2017) | no assertion criteria provided |
| - GRCh37:
- ChrMT:10105-15066
- GRCh38:
- ChrMT:10105-15066
| MT-CYB, MT-ND3, MT-ND4, MT-TH, MT-TL2, MT-TR, MT-TS2, MT-ND4L, MT-ND5, MT-ND6, MT-TE | | Mitochondrial disease | Pathogenic (May 22, 2017) | no assertion criteria provided |
| - GRCh37:
- ChrMT:10947-15537
- GRCh38:
- ChrMT:10947-15537
| MT-TL2, MT-TS2, MT-CYB, MT-ND4, MT-ND5, MT-ND6, MT-TE, MT-TH | | Pearson syndrome | Pathogenic | criteria provided, single submitter |
| - GRCh37:
- ChrMT:11263-15374
- GRCh38:
- ChrMT:11263-15374
| MT-ND6, MT-TE, MT-TH, MT-CYB, MT-ND4, MT-ND5, MT-TL2, MT-TS2 | | Mitochondrial disease | Pathogenic (May 22, 2017) | no assertion criteria provided |
| - GRCh37:
- ChrMT:12114-14420
- GRCh38:
- ChrMT:12114-14420
| MT-ND4, MT-ND5, MT-ND6, MT-TH, MT-TL2, MT-TS2 | | Mitochondrial disease | Pathogenic (May 22, 2017) | no assertion criteria provided |
| - GRCh37:
- ChrMT:14153
- GRCh38:
- ChrMT:14153
| MT-ND6 | | Leigh syndrome | Likely benign (Oct 17, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:14154
- GRCh38:
- ChrMT:14154
| MT-ND6 | | Leigh syndrome | Uncertain significance (Oct 17, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:14162
- GRCh38:
- ChrMT:14162
| MT-ND6 | | Leigh syndrome | Benign (Oct 17, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:14163
- GRCh38:
- ChrMT:14163
| MT-ND6 | | Leigh syndrome | Benign (Oct 17, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:14178
- GRCh38:
- ChrMT:14178
| MT-ND6 | | Leigh syndrome | Benign (Oct 17, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:14180
- GRCh38:
- ChrMT:14180
| MT-ND6 | | Leigh syndrome | Benign (Oct 17, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:14180
- GRCh38:
- ChrMT:14180
| MT-ND6 | | Leigh syndrome | Uncertain significance (Oct 17, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:14181
- GRCh38:
- ChrMT:14181
| MT-ND6 | | Leigh syndrome | Likely benign (Oct 17, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:14189
- GRCh38:
- ChrMT:14189
| MT-ND6 | | Leigh syndrome | Likely benign (Oct 17, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:14193
- GRCh38:
- ChrMT:14193
| MT-ND6 | | Leigh syndrome | Likely benign (Oct 17, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:14198
- GRCh38:
- ChrMT:14198
| MT-ND6 | | Leigh syndrome | Benign (Oct 17, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:14199
- GRCh38:
- ChrMT:14199
| MT-ND6 | | Leigh syndrome | Uncertain significance (Oct 17, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:14207
- GRCh38:
- ChrMT:14207
| MT-ND6 | | Leigh syndrome | Benign (Oct 17, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:14210
- GRCh38:
- ChrMT:14210
| MT-ND6 | | Leigh syndrome | Uncertain significance (Oct 17, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:14211
- GRCh38:
- ChrMT:14211
| MT-ND6 | | Leigh syndrome | Benign (Oct 17, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:14225
- GRCh38:
- ChrMT:14225
| MT-ND6 | | Leigh syndrome | Uncertain significance (Oct 17, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:14226
- GRCh38:
- ChrMT:14226
| MT-ND6 | | Leigh syndrome | Benign (Oct 17, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:14231
- GRCh38:
- ChrMT:14231
| MT-ND6 | | Leigh syndrome | Uncertain significance (Oct 17, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:14234
- GRCh38:
- ChrMT:14234
| MT-ND6 | | Leigh syndrome | Uncertain significance (Oct 17, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:14243-14244
- GRCh38:
- ChrMT:14243-14244
| MT-ND6 | | Oxyphilic adenoma | Pathogenic (Sep 15, 2011) | no assertion criteria provided |
| - GRCh37:
- ChrMT:14249
- GRCh38:
- ChrMT:14249
| MT-ND6 | | Leigh syndrome | Benign (Oct 17, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:14256
- GRCh38:
- ChrMT:14256
| MT-ND6 | | Leigh syndrome | Benign (Oct 17, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:14258
- GRCh38:
- ChrMT:14258
| MT-ND6 | | Leigh syndrome | Benign (Oct 17, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:14259
- GRCh38:
- ChrMT:14259
| MT-ND6 | | Leigh syndrome | Benign (Oct 17, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:14276
- GRCh38:
- ChrMT:14276
| MT-ND6 | | Leigh syndrome | Uncertain significance (Oct 17, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:14279
- GRCh38:
- ChrMT:14279
| MT-ND6 | | Leigh syndrome | Uncertain significance (Oct 17, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:14280
- GRCh38:
- ChrMT:14280
| MT-ND6 | | Leigh syndrome | Likely benign (Oct 17, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:14280
- GRCh38:
- ChrMT:14280
| MT-ND6 | | Leigh syndrome | Benign (Oct 17, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:14297
- GRCh38:
- ChrMT:14297
| MT-ND6 | | Leigh syndrome | Uncertain significance (Oct 17, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:14301
- GRCh38:
- ChrMT:14301
| MT-ND6 | | Leigh syndrome | Uncertain significance (Oct 17, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:14307
- GRCh38:
- ChrMT:14307
| MT-ND6 | | Leigh syndrome | Uncertain significance (Oct 17, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:14312
- GRCh38:
- ChrMT:14312
| MT-ND6 | | Leigh syndrome | Benign (Oct 17, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:14315
- GRCh38:
- ChrMT:14315
| MT-ND6 | | Leigh syndrome | Benign (Oct 17, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:14318
- GRCh38:
- ChrMT:14318
| MT-ND6 | | Leigh syndrome | Benign (Oct 17, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:14319
- GRCh38:
- ChrMT:14319
| MT-ND6 | | Leigh syndrome | Benign (Oct 17, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:14325
- GRCh38:
- ChrMT:14325
| MT-ND6 | | Leigh syndrome | Benign (Oct 17, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:14328
- GRCh38:
- ChrMT:14328
| MT-ND6 | | Leigh syndrome | Uncertain significance (Oct 17, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:14334
- GRCh38:
- ChrMT:14334
| MT-ND6 | | Leigh syndrome | Likely benign (Oct 17, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:14339
- GRCh38:
- ChrMT:14339
| MT-ND6 | | Leigh syndrome | Uncertain significance (Oct 17, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:14340
- GRCh38:
- ChrMT:14340
| MT-ND6 | | Leigh syndrome | Likely benign (Oct 17, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:14348
- GRCh38:
- ChrMT:14348
| MT-ND6 | | Leigh syndrome | Likely benign (Oct 17, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:14357
- GRCh38:
- ChrMT:14357
| MT-ND6 | | Leigh syndrome | Likely benign (Oct 17, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:14372
- GRCh38:
- ChrMT:14372
| MT-ND6 | | Acute megakaryocytic leukemia, Mediastinal germ cell tumor | Uncertain significance (Oct 22, 2015) | no assertion criteria provided |
| - GRCh37:
- ChrMT:14375
- GRCh38:
- ChrMT:14375
| MT-ND6 | | Leigh syndrome | Uncertain significance (Oct 17, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:14382
- GRCh38:
- ChrMT:14382
| MT-ND6 | | Leigh syndrome | Uncertain significance (Oct 17, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:14384
- GRCh38:
- ChrMT:14384
| MT-ND6 | | Leigh syndrome | Benign (Oct 17, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:14393
- GRCh38:
- ChrMT:14393
| MT-ND6 | | not provided, Leigh syndrome | Benign/Likely benign (Oct 17, 2019) | criteria provided, multiple submitters, no conflicts |
| - GRCh37:
- ChrMT:14405
- GRCh38:
- ChrMT:14405
| MT-ND6 | | Leigh syndrome | Benign (Oct 17, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:14417
- GRCh38:
- ChrMT:14417
| MT-ND6 | | Leigh syndrome | Benign (Oct 17, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:14420
- GRCh38:
- ChrMT:14420
| MT-ND6 | | Leigh syndrome | Likely benign (Oct 17, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:14423
- GRCh38:
- ChrMT:14423
| MT-ND6 | | Leigh syndrome | Uncertain significance (Oct 17, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:14433
- GRCh38:
- ChrMT:14433
| MT-ND6 | | Leigh syndrome | Benign (Oct 17, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:14444
- GRCh38:
- ChrMT:14444
| MT-ND6 | | Leigh syndrome | Uncertain significance (Oct 17, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:14453
- GRCh38:
- ChrMT:14453
| MT-ND6 | | Mitochondrial disease | Likely pathogenic (Jun 30, 2022) | reviewed by expert panel FDA Recognized Database |
| - GRCh37:
- ChrMT:14459
- GRCh38:
- ChrMT:14459
| MT-ND6 | | Mitochondrial disease | Pathogenic (Nov 1, 2021) | reviewed by expert panel FDA Recognized Database |
| - GRCh37:
- ChrMT:14462
- GRCh38:
- ChrMT:14462
| MT-ND6 | | Leigh syndrome | Likely benign (Oct 17, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:14465
- GRCh38:
- ChrMT:14465
| MT-ND6 | | Juvenile myopathy, encephalopathy, lactic acidosis AND stroke | Likely pathogenic (Oct 17, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:14466
- GRCh38:
- ChrMT:14466
| MT-ND6 | | Leigh syndrome | Uncertain significance (Oct 17, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:14468
- GRCh38:
- ChrMT:14468
| MT-ND6 | | Leigh syndrome | Uncertain significance (Oct 17, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:14470
- GRCh38:
- ChrMT:14470
| MT-ND6 | | not provided | Likely benign (May 29, 2015) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:14476
- GRCh38:
- ChrMT:14476
| MT-ND6 | | not provided | Benign (Jan 3, 2017) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:14477
- GRCh38:
- ChrMT:14477
| MT-ND6 | | Constriction of peripheral visual field, Abnormality of brain morphology, Vertigo, Muscle spasm, Paresthesia, Cognitive impairment, Headache | Uncertain significance (Jan 1, 2017) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:14482
- GRCh38:
- ChrMT:14482
| MT-ND6 | | Mitochondrial disease | Likely pathogenic (Jul 11, 2022) | reviewed by expert panel FDA Recognized Database |
| - GRCh37:
- ChrMT:14482
- GRCh38:
- ChrMT:14482
| MT-ND6 | | Mitochondrial disease | Likely pathogenic (Jun 30, 2022) | reviewed by expert panel FDA Recognized Database |
| - GRCh37:
- ChrMT:14484
- GRCh38:
- ChrMT:14484
| MT-ND6 | | Leigh syndrome | Uncertain significance (Oct 17, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:14484
- GRCh38:
- ChrMT:14484
| MT-ND6 | | Mitochondrial disease | Pathogenic (Sep 12, 2022) | reviewed by expert panel FDA Recognized Database |
| - GRCh37:
- ChrMT:14487
- GRCh38:
- ChrMT:14487
| MT-ND6 | | Mitochondrial disease | Pathogenic (Aug 8, 2022) | reviewed by expert panel FDA Recognized Database |
| - GRCh37:
- ChrMT:14495
- GRCh38:
- ChrMT:14495
| MT-ND6 | | Mitochondrial disease | Likely pathogenic (Jun 30, 2022) | reviewed by expert panel FDA Recognized Database |
| - GRCh37:
- ChrMT:14498
- GRCh38:
- ChrMT:14498
| MT-ND6 | | Leigh syndrome | Uncertain significance (Oct 17, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:14502
- GRCh38:
- ChrMT:14502
| MT-ND6 | | Leigh syndrome | Benign (Oct 17, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:14512-14513
- GRCh38:
- ChrMT:14512-14513
| MT-ND6 | | Mitochondrial disease | Pathogenic (Dec 9, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:14514
- GRCh38:
- ChrMT:14514
| MT-ND6 | | Leigh syndrome | Benign (Oct 17, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:14523
- GRCh38:
- ChrMT:14523
| MT-ND6 | | Leigh syndrome | Uncertain significance (Oct 17, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:14529
- GRCh38:
- ChrMT:14529
| MT-ND6 | | Leigh syndrome | Likely benign (Oct 17, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:14544
- GRCh38:
- ChrMT:14544
| MT-ND6 | | Leigh syndrome | Uncertain significance (Oct 17, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:14552
- GRCh38:
- ChrMT:14552
| MT-ND6 | | Leigh syndrome | Benign (Oct 17, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:14553
- GRCh38:
- ChrMT:14553
| MT-ND6 | | Leigh syndrome | Benign (Oct 17, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:14562
- GRCh38:
- ChrMT:14562
| MT-ND6 | | Leigh syndrome | Benign (Oct 17, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:14563
- GRCh38:
- ChrMT:14563
| MT-ND6 | | Mitochondrial cytopathy | Uncertain significance (Nov 21, 2016) | no assertion criteria provided |
| - GRCh37:
- ChrMT:14564
- GRCh38:
- ChrMT:14564
| MT-ND6 | | Leigh syndrome | Likely benign (Oct 17, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:14568
- GRCh38:
- ChrMT:14568
| MT-ND6 | | Mitochondrial disease | Likely pathogenic (Jun 30, 2022) | reviewed by expert panel FDA Recognized Database |
| - GRCh37:
- ChrMT:14571
- GRCh38:
- ChrMT:14571
| MT-ND6 | | Leigh syndrome | Benign (Oct 17, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:14573
- GRCh38:
- ChrMT:14573
| MT-ND6 | | Leigh syndrome | Uncertain significance (Oct 17, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:14574
- GRCh38:
- ChrMT:14574
| MT-ND6 | | Leigh syndrome | Benign (Oct 17, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:14576
- GRCh38:
- ChrMT:14576
| MT-ND6 | | Leigh syndrome | Uncertain significance (Oct 17, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:14577
- GRCh38:
- ChrMT:14577
| MT-ND6 | | Leigh syndrome | Benign (Oct 17, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:14577
- GRCh38:
- ChrMT:14577
| MT-ND6 | | Leigh syndrome | Likely benign (Oct 17, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:14582
- GRCh38:
- ChrMT:14582
| MT-ND6 | | Leigh syndrome | Benign (Oct 17, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:14596
- GRCh38:
- ChrMT:14596
| MT-ND6 | | Leber optic atrophy and dystonia | Pathogenic (Apr 1, 1996) | no assertion criteria provided |
| - GRCh37:
- ChrMT:14597
- GRCh38:
- ChrMT:14597
| MT-ND6 | | not specified, Dystonic disorder, Dysarthria, Leigh syndrome | Conflicting interpretations of pathogenicity (May 4, 2022) | criteria provided, conflicting interpretations |
| - GRCh37:
- ChrMT:14598
- GRCh38:
- ChrMT:14598
| MT-ND6 | | Leigh syndrome, Parkinsonism, Blindness
| Conflicting interpretations of pathogenicity (Oct 17, 2019) | criteria provided, conflicting interpretations |
| - GRCh37:
- ChrMT:14601
- GRCh38:
- ChrMT:14601
| MT-ND6 | | Leigh syndrome | Uncertain significance (Oct 17, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:14615
- GRCh38:
- ChrMT:14615
| MT-ND6 | | Leigh syndrome | Uncertain significance (Oct 17, 2019) | criteria provided, single submitter |